NCT07848243RecruitingPhase 2
Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
\[18F\]F-PDL1-3 molecular probe was used to detect the expression of PD-L1 in primary and metastatic tumors of patients with solid tumors. The heterogeneity of PD-L1 expression in the same lesion and different lesions was further evaluated, and the changes of PD-L1 expression in the course of the disease were observed. This method is helpful for the screening of patients with solid tumors with high PD-L1 expression, efficacy monitoring, and early warning of drug resistance and/or recurrence or metastasis, and ultimately achieve individualized targeted therapy of tumors
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 18 Sept 2026
- Start date
- 1 Feb 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Melanoma, Lung cancer
- NCT number
- NCT07848243
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 1 Feb 2026 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known allergy to the investigational drug or its excipients in the study treatment; Other circumstances considered by the investigator to be inappropriate for trial participation.
Other illness
- Claustrophobia or other mental illness.
Other
- Severe abnormal liver and kidney function.
- Pre-pregnancy, pregnant and lactating women.
- Unable to lie flat for half an hour.
- Refusal to be a clinical investigator.
Who the study is looking for
- Age \>18 years old, ECOG score 0 or 1;
- subjects with pathologically confirmed solid tumors (lung cancer, cervical cancer, melanoma, breast cancer, gastrointestinal tumor, etc.), recent recurrence or suspected recurrence of previous solid tumors;
- There was at least one measurable target lesion according to RECIST1.1 criteria;
- Predicted survival time ≥12 weeks;
- Blood routine, liver and kidney function meet the following standards: see the study protocol for specific requirements;
- Women must be using an effective contraceptive method (effective contraception means sterilization, intrauterine hormonal devices, condoms, contraceptives/pills, abstinence, or partner's removal of the vas deferentia) during the study and for 6 months after the study; Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period;
- Subjects can fully understand and voluntarily participate in this experiment, and sign an informed consent. Compliance was good.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Cancer Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.